dc.contributor.author |
Lleó, Alberto |
dc.contributor.author |
Pegueroles, Jordi |
dc.contributor.author |
Karikari, Thomas K. |
dc.contributor.author |
Carmona Iragui, María |
dc.contributor.author |
Ashton, Nicholas J. |
dc.contributor.author |
Montal, Victor |
dc.contributor.author |
Barroeta, Isabel |
dc.contributor.author |
Lantero-Rodríguez, Juan |
dc.contributor.author |
Videla Toro, Laura |
dc.contributor.author |
Altuna-Azkargorta, Miren |
dc.contributor.author |
Benejam, Bessy |
dc.contributor.author |
Fernandez, Susana |
dc.contributor.author |
Valldeneu, Silvia |
dc.contributor.author |
Garzón, Diana |
dc.contributor.author |
Bejanin, Alexandre |
dc.contributor.author |
Iulita, M. Florencia |
dc.contributor.author |
Camacho, Valle |
dc.contributor.author |
Medrano-Martorell, Santiago |
dc.contributor.author |
Belbin, Olivia |
dc.contributor.author |
Clarimón, Jordi |
dc.contributor.author |
Lehmann, Sylvain |
dc.contributor.author |
Alcolea, Daniel |
dc.contributor.author |
Blesa, Rafael |
dc.contributor.author |
Blennow, Kaj |
dc.contributor.author |
Fortea, Juan |
dc.contributor.author |
Zetterberg, Henrik |
dc.contributor.author |
Universitat Autònoma de Barcelona |
dc.date |
2021 |
dc.identifier |
https://ddd.uab.cat/record/256506 |
dc.identifier |
urn:10.1038/s41467-021-24319-x |
dc.identifier |
urn:oai:ddd.uab.cat:256506 |
dc.identifier |
urn:pmcid:PMC8280160 |
dc.identifier |
urn:pmc-uid:8280160 |
dc.identifier |
urn:pmid:34262030 |
dc.identifier |
urn:oai:pubmedcentral.nih.gov:8280160 |
dc.format |
application/pdf |
dc.language |
eng |
dc.publisher |
|
dc.relation |
Agència de Gestió d'Ajuts Universitaris i de Recerca SLT006/17/00119 |
dc.relation |
Agència de Gestió d'Ajuts Universitaris i de Recerca SLT006/17/95 |
dc.relation |
Agència de Gestió d'Ajuts Universitaris i de Recerca SLT006/17/00125 |
dc.relation |
Agència de Gestió d'Ajuts Universitaris i de Recerca SLT002/16/00408 |
dc.relation |
European Commission 860197 |
dc.relation |
Instituto de Salud Carlos III PI14/01126 |
dc.relation |
Instituto de Salud Carlos III PI17/01019 |
dc.relation |
Instituto de Salud Carlos III PI13/01532 |
dc.relation |
Instituto de Salud Carlos III PI16/01825 |
dc.relation |
Instituto de Salud Carlos III PI18/00335 |
dc.relation |
Instituto de Salud Carlos III PI18/00435 |
dc.relation |
Instituto de Salud Carlos III INT19/00016 |
dc.relation |
Instituto de Salud Carlos III PI15/01618 |
dc.relation |
Instituto de Salud Carlos III PI14/1561 |
dc.relation |
Instituto de Salud Carlos III AC19/00103 |
dc.relation |
Instituto de Salud Carlos III CP20/00038 |
dc.relation |
Ministerio de Economía, Industria y Competitividad IJCI-2017-32609 |
dc.relation |
Nature communications ; Vol. 12 (july 2021) |
dc.rights |
open access |
dc.rights |
Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original. |
dc.rights |
https://creativecommons.org/licenses/by/4.0/ |
dc.subject |
Alzheimer's disease |
dc.subject |
Predictive markers |
dc.title |
Phosphorylated tau181 in plasma as a potential biomarker for Alzheimer's disease in adults with Down syndrome |
dc.type |
Article |
dc.description.abstract |
Altres ajuts: Fundació La Marató de TV3 (20141210 to J.F., 044412 to R.B. and 201437.10 to R.R.). |
dc.description.abstract |
Plasma tau phosphorylated at threonine 181 (p-tau181) predicts Alzheimer's disease (AD) pathology with high accuracy in the general population. In this study, we investigated plasma p-tau181 as a biomarker of AD in individuals with Down syndrome (DS). We included 366 adults with DS (240 asymptomatic, 43 prodromal AD, 83 AD dementia) and 44 euploid cognitively normal controls. We measured plasma p-tau181 with a Single molecule array (Simoa) assay. We examined the diagnostic performance of p-tau181 for the detection of AD and the relationship with other fluid and imaging biomarkers. Plasma p-tau181 concentration showed an area under the curve of 0.80 [95% CI 0.73-0.87] and 0.92 [95% CI 0.89-0.95] for the discrimination between asymptomatic individuals versus those in the prodromal and dementia groups, respectively. Plasma p-tau181 correlated with atrophy and hypometabolism in temporoparietal regions. Our findings indicate that plasma p-tau181 concentration can be useful to detect AD in DS. Plasma tau phosphorylated at threonine 181 (p-tau181) predicts Alzheimer's disease (AD) pathology. Here, the authors investigated whether plasma ptau181 could be a potential biomarker of AD in individuals with Down syndrome (DS) and find plasma p-tau181 can detect AD in DS adults. |